君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

已收盘 06-09 16:08:13

16.140

-0.590

-3.53%

最高16.800	最低15.750	成交量461.58万
今开17.000	昨收16.730	日振幅6.28%
总市值165.76亿	流通市值41.96亿	总股本10.27亿
成交额7,474万	换手率1.78%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":16.14,"timestamp":1780992493001,"preClose":16.73,"halted":0,"volume":4615800,"delay":0,"changeRate":-0.03526598924088463,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"已收盘","change":-0.59,"latestTime":"06-09 16:08:13","open":17,"high":16.8,"low":15.75,"amount":74741836,"amplitude":0.062762,"askPrice":16.17,"askSize":10000,"bidPrice":16.14,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":-0.691,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781055000000},"marketStatusCode":5,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":16.73,"openAndCloseTimeList":[[1780968600000,1780977600000],[1780981200000,1780992000000]],"volumeRatio":1.210484,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":29.29,"timestamp":1780988400000,"preClose":28.93,"halted":0,"volume":11196300,"delay":0,"premium":"-52.36"}},"requestUrl":"/m/hq/s/01877/wiki","defaultTab":"wiki","newsList":[{"id":"2641483963","title":"6月8日君实生物现1笔大宗交易 机构净买入1982.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641483963?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:58","pubTimestamp":1780912683,"startTime":"0","endTime":"0","summary":"证券之星消息，6月8日君实生物发生大宗交易，交易数据如下：大宗交易成交价格28.73元，相对当日收盘价折价0.69%，成交69万股，成交金额1982.37万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。近三个月该股共发生4笔大宗交易，合计成交1.75万手，折价成交1笔。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144895873","title":"君实生物子公司部分项目持股结构变更获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1144895873","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144895873?lang=zh_cn&edition=full","pubTime":"2026-06-05 22:12","pubTimestamp":1780668771,"startTime":"0","endTime":"0","summary":"君实生物宣布，其部分子项目的实施主体持股结构变更方案已获通过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1583","BK0239","01877","BK1161","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106400533","title":"上海君实生物 - 君研弘石拟增资1亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1106400533","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106400533?lang=zh_cn&edition=full","pubTime":"2026-06-05 22:10","pubTimestamp":1780668625,"startTime":"0","endTime":"0","summary":"上海君实生物科技股份有限公司旗下子公司君研弘石计划增加注册资本1亿元人民币。此举旨在提升其运营资本与业务发展能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01877","BK1583","BK0239","BK1161","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143811","title":"君实生物：公司将于2026年6月26日召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143811","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641143811?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:40","pubTimestamp":1780663200,"startTime":"0","endTime":"0","summary":"证券日报网讯6月5日，君实生物发布公告称，公司将于2026年6月26日召开2025年年度股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-05/doc-iniakmqn8278591.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-06-05/doc-iniakmqn8278591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","01877","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148898","title":"君实生物：副总姚盛转任非执行董事 独董张淳届满离任 提名陈良为独董候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148898","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148898?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:08","pubTimestamp":1780661280,"startTime":"0","endTime":"0","summary":"6月5日，君实生物（688180/01877）发布公告，姚盛因其他工作安排，申请辞去副总经理及部分子公司职务，其辞职后将被调任为非执行董事。同时，独立非执行董事张淳因任期届满离任，其离任后不在公司继续任职，公司已提名陈良为独立非执行董事候选人。公告中提到，在姚盛离职后，其负责的工作将由执行董事、总经理兼首席执行官邹建军和执行董事、副总经理张卓兵共同承担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606053762146079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1583","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117627","title":"君实生物：拟以知识产权及资产作价5308.11万元对外投资关联公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641117627?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:21","pubTimestamp":1780658477,"startTime":"0","endTime":"0","summary":"君实生物(688180.SH)公告称，公司及全资子公司拟以知识产权权益及实物资产作价5308.11万元认购上海致域生物医药有限公司新增注册资本25万元。同时，四名天使轮投资人拟以1500万美元认购合资公司新增注册资本，完成后公司预计持有合资公司14.55%股权。本次交易构成关联交易，尚需股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500035476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","01877","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148450351","title":"君实生物5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1148450351","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148450351?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:48","pubTimestamp":1780476485,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司于2026年6月3日发布截至2026年5月31日的股份变动月报表。根据公告，报告期内公司股本结构保持不变。报告期末，H股已发行股份260,295,700股，A股已发行股份765,578,300股，库存股815,871股，总体数量与上月底保持一致，未发生新增、回购、注销或库藏股数量变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937525","title":"破发股君实生物跌3.53% 2020年上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937525","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640937525?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:00","pubTimestamp":1780304404,"startTime":"0","endTime":"0","summary":"中国经济网北京6月1日讯 君实生物 今日收报33.03元，跌幅3.53%。该股目前处于破发状态。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。　　经计算，君实生物两次募集资金合计86.12亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260601/32266246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1583","01877","IPOS","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640934504","title":"智通AH统计|6月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2640934504","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640934504?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:15","pubTimestamp":1780301706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止6月1日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为671.43%、372.38%、313.93%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-33.22%、-19.56%、-4.81%。其中东北电气、新天绿色能源、晨鸣纸业的偏离值位居前三，分别为93.47%、53.80%、38.74%；另外，龙旗科技、胜宏科技、福莱特玻璃的偏离值位居后三，分别为-18.29%、-16.28%、-14.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01349","03678","01057","03347","02628","06865","399300","LU2778985437.USD","PAImain","03986","02039","01375","BK1170","LU0831093199.SGD","82318","01033","01877","00916","02238","PNGAY","03143","03145","02476","601318","00763","01330","00300","00588","02318","01108","00568","01276","02338","HPAD.SI","02218","IE0031814852.USD","03750","IE00BZ08YS42.EUR","02359","03968","159982","EWH","09611","03328","01812","00699","00042","00956","LU0228367735.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601948","title":"每周股票复盘：君实生物（688180）特瑞普利单抗围手术期治疗达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601948","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639601948?lang=zh_cn&edition=full","pubTime":"2026-05-31 01:36","pubTimestamp":1780162573,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，君实生物报收于34.24元，较上周的37.13元下跌7.78%。本周，君实生物5月25日盘中最高价报37.22元。公司公告汇总君实生物自愿披露关于特瑞普利单抗联合化疗用于II-III期可切除非小细胞肺癌患者围手术期治疗的III期临床研究达到最终分析主要研究终点的公告。公司计划递交补充申请，拟将适应症扩展至II-III期患者。该药已在国内获批13项适应症，其中12项纳入国家医保目录，并在多个国家和地区获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1583","688180","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638854800","title":"君实生物（688180）披露特瑞普利单抗围手术期治疗非小细胞肺癌III期临床研究达主要终点，5月26日股价下跌3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638854800","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638854800?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:17","pubTimestamp":1779805035,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，君实生物报收于35.2元，较前一交易日下跌3.48%，最新总市值为361.39亿元。该股当日开盘36.05元，最高36.62元，最低34.79元，成交额达5.04亿元，换手率为1.86%。近日，上海君实生物医药科技股份有限公司发布公告称，其产品特瑞普利单抗联合化疗用于II-III期可切除非小细胞肺癌患者围手术期治疗的III期临床研究已完成最终分析，主要研究终点II-III期人群的无事件生存期、主要病理学缓解率及III期人群MPR率均达到预设优效界值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","688180","BK0239","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317641","title":"君实生物：2025年营业收入24.98亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317641","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637317641?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:20","pubTimestamp":1779456000,"startTime":"0","endTime":"0","summary":"南财智讯5月22日电，君实生物（01877.HK）公告，截至2025年12月31日止年度，公司总收益为24.98亿元人民币；年内溢利数据未披露；每股基本盈利数据未披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747024570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387686","title":"君实生物：特瑞普利单抗注射液第13项适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387686","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637387686?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:36","pubTimestamp":1779359760,"startTime":"0","endTime":"0","summary":"5月21日，君实生物（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞普利单抗（商品名：拓益?）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605213745358513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1161","BK1583","01877","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636424831","title":"君实生物：JS015单药在晚期实体瘤中首次人体研究已完成 联合治疗胃肠道肿瘤中II期临床研究在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2636424831","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636424831?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:09","pubTimestamp":1779181776,"startTime":"0","endTime":"0","summary":"【君实生物：JS015单药在晚期实体瘤中首次人体研究已完成 联合治疗胃肠道肿瘤中II期临床研究在进行中】君实生物（688180.SH）5月19日在投资者互动平台表示，JS015（DKK1单抗）单药在晚期实体瘤中的首次人体研究已经完成，联合治疗在胃肠道肿瘤中的II期临床研究正在进行中，相关临床数据请以公司公告或学术会议报告为准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193742049795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193742049795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","01877","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636352158","title":"君实生物：截至2025年12月31日，公司持有南京英派药业股份有限公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636352158","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636352158?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:49","pubTimestamp":1779176985,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好！贵司目前有投资英派药业的股份吗？如有收益何时能并入财报？对君实的业绩是否有影响？君实生物（688180.SH）5月19日在投资者互动平台表示，截至2025年12月31日，公司持有南京英派药业股份有限公司股份，具体财务影响请以公司未来定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741912174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741912174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1583","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636352388","title":"君实生物：目前公司已建立多特异性抗体研发平台并正在积极开展相关药物研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636352388","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636352388?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:49","pubTimestamp":1779176978,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问公司今年有没有三抗管线进入临床？君实生物（688180.SH）5月19日在投资者互动平台表示，目前公司已建立多特异性抗体研发平台并正在积极开展相关药物研发工作。如有相关候选药物进入研发阶段，公司将严格按照相关规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741911594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741911594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","LU0456827905.SGD","LU0634319403.HKD","LU0456846285.SGD","LU1719994722.HKD","LU1993786604.SGD","BK1588","LU0072913022.USD","02269","LU0572944931.SGD","IE00B031HY20.USD","01877","LU0348767384.USD","AGIX","LU0067412154.USD","LU0326950275.SGD","LU0417516738.SGD","LU0516422952.EUR","01093","09926","IE00BPRC5H50.USD","BK1589","02142","SG9999002562.SGD","LU0856984785.SGD","LU1152091168.USD","09995","02616","LU0140636845.USD","AIPO","01177","09688","LU1152091754.HKD","06978","BK1161","01801","LU1303224171.USD","LU0561508036.HKD","159992","LU0348827113.USD","06160","CHAT","BK1583","LU2097828631.EUR","LU1226287792.SGD","LU0315179316.USD","LU1880383366.USD","LU1226288170.HKD","LU1960683339.HKD","ARTY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636044929","title":"国金证券：给予君实生物买入评级，目标价53.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636044929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636044929?lang=zh_cn&edition=full","pubTime":"2026-05-18 13:55","pubTimestamp":1779083716,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对君实生物进行研究并发布了研究报告《公司业绩拐点已至，IO联合ADC构筑价值壁垒》，给予君实生物买入评级，目标价53.0元。采用DCF估值法，给予目标价53.00元/股，首次覆盖，给予“买入”评级。　　风险提示　　药品销售不及预期；临床试验进展不及预期；临床数据不及预期最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为53.12。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","IE00B0JY6N72.USD","01177","LU0348827113.USD","LU1152091168.USD","LU0979878070.USD","02269","01877","LU0561508036.HKD","BK1574","LU0516423174.USD","BK1161","02142","LU0417516738.SGD","02616","159992","IE00BZ08YS42.EUR","LU0326950275.SGD","09926","LU1969619763.USD","LU0588546209.SGD","LU1242518931.SGD","LU0456827905.SGD","LU2097828474.EUR","IE00BZ08YT58.USD","LU1242518857.USD","LU1152091754.HKD","LU1303224171.USD","IE00B5MMRT66.SGD","LU0039217434.USD","LU2097828631.EUR","06185","LU0516422952.EUR","LU1993786604.SGD","09995","IE00B543WZ88.USD","LU0359202008.SGD","BK1141","01093","06160","LU1226287875.USD","LU2097828557.USD","BK1588","09688","LU1688375341.USD","01801","601066","SG9999002562.SGD","IE00BZ08YR35.GBP","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771583","title":"开源证券：首次覆盖君实生物给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635771583?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:55","pubTimestamp":1778817352,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,聂媛媛近期对君实生物进行研究并发布了研究报告《公司首次覆盖报告：全面布局IO+ADC 2.0时代，争新一代实体瘤SOC》，首次覆盖君实生物给予买入评级。我们预计公司2026-2028年营业收入分别为32.48/42.22/54.89亿元，EPS分别为-0.04/0.44/1.04元，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为53.12。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500020133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.1354},{"period":"1month","weight":-0.3166},{"period":"3month","weight":-0.1614},{"period":"6month","weight":-0.2881},{"period":"1year","weight":-0.2164},{"period":"ytd","weight":-0.216}],"compareEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.0346},{"period":"1year","weight":0.0363},{"period":"ytd","weight":-0.038}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.041685},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}